New NCI Grant to Foster Development of Novel Therapy in Metastatic Colorectal Cancer
-
By
May 2, 2024
-
1 min
-
1
Case Western Reserve University's School of Medicine received a 5-year $1.84 million grant from the NCI to investigate the LRG1 protein's role in colorectal cancer growth.
-
2
Secretion of the LRG1 protein from the liver may promote colorectal cancer metastasis to the liver, leading to worse treatment responses in patients with liver metastases.
-
3
The researchers aim to identify key mechanisms driving cancer cell proliferation and inhibit tumor growth using antibodies to prevent liver and colorectal cancer cell communication.
-
Case Western Reserve University's School of Medicine has been granted a 5-year $1.84 million from the NCI to investigate the role of the LRG1 protein in the growth of colorectal cancer and potentially develop a novel treatment for patients with metastatic colorectal cancer. Their research discovered that the secretion of LRG1 protein from the liver may cause vascular dysfunction and promote colorectal cancer metastasis to the liver, leading to worse treatment responses in patients with liver metastases. The researchers aim to identify key mechanisms driving cancer cell proliferation and inhibit tumor growth using antibodies to prevent liver and colorectal cancer cell communication.
-
1
Case Western Reserve University's School of Medicine received a 5-year $1.84 million grant from the NCI to investigate the LRG1 protein's role in colorectal cancer growth.
-
2
Secretion of the LRG1 protein from the liver may promote colorectal cancer metastasis to the liver, leading to worse treatment responses in patients with liver metastases.
-
3
The researchers aim to identify key mechanisms driving cancer cell proliferation and inhibit tumor growth using antibodies to prevent liver and colorectal cancer cell communication.
Listen Tab content
